This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E24.3 (ectopic ACTH syndrome) | Special Copayment Reduction: V114 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | Ectopic adrenocorticotropic hormone syndrome (Ectopic ACTH syndrome), paraneoplastic Cushing's syndrome, tumor-associated ACTH secretion, ectopic ACTH production |
| C. Adult onset | Likelihood of first presentation in adulthood very high — found at the same time as or after the diagnosis of the primary tumor (lung cancer, bronchial carcinoid, etc.), and common in middle to old age. |
| 1. History | 1928: Brown first reported the association between a lung tumor and adrenal hyperfunction → 1962: Meador et al. elucidated the mechanism of ectopic ACTH secretion → advances in ACTH measurement and imaging technology systematized diagnosis. |
| 2. Causes | Autonomous secretion of ACTH or the ACTH precursor (POMC) by non-pituitary tumors. Main causes: small cell lung cancer (50%), bronchial carcinoid, thymic carcinoid, pancreatic neuroendocrine tumor, pheochromocytoma. |
| 3. Genetics | Somatic variants of the primary tumor (SCLC: TP53, RB1; carcinoid: MEN1, DAXX/ATRX). Can occur in familial neuroendocrine tumors associated with MEN1, VHL and RET germline variants. |
| 4. General epidemiology | Ectopic ACTH syndrome accounts for about 10–20% of all endogenous Cushing syndrome. Present in 1–5% of small cell lung cancers. Also occurs in 2–3% of carcinoid tumors. Male predominance (lung cancer–related form). |
| 5. Pathophysiology | Ectopic expression of the POMC gene in non-pituitary neuroendocrine tumor cells → excessive ACTH secretion (no pituitary-dependent regulation) → stimulation of both adrenal glands → extremely high cortisol → normal negative feedback fails to operate. |
| 6. Symptoms | Acute presentation is characteristic. Proximal muscle weakness (severe), hypokalemia (hypokalemic alkalosis), severe hypertension, diabetes, generalized edema, skin hyperpigmentation. Typical cushingoid appearance may be absent (rapid course). |
| 7. Signs | Extremely high serum cortisol, extremely high plasma ACTH (>200 pg/mL common), severe hypokalemia (<3.0 mEq/L), hyperglycemia, alkalemia. No response to the high-dose dexamethasone suppression test. |
| 8. Screening | Suspect in patients with unexplained hypokalemia + hypertension + muscle weakness. Measure serum cortisol, ACTH and UFC. In patients with suspected neuroendocrine tumors, evaluate concurrently for associated Cushing syndrome. |
| 9. Diagnosis | Confirm hypercortisolism → elevated ACTH (dependent) → 8 mg dexamethasone suppression test (no suppression) → IPSS (low central:peripheral ratio) → tumor imaging (CT/MRI, somatostatin receptor scintigraphy, FDG-PET). |
| 10. Treatment | Removal of the primary tumor is the top priority. If unresectable: cortisol synthesis inhibitors (ketoconazole, metyrapone, etomidate IV), bilateral adrenalectomy. Chemotherapy (SCLC). Immediate correction of hypokalemia is essential. |
| 11. Prognosis | Varies greatly with the malignancy of the primary tumor. SCLC-related form: median survival of a few months. Carcinoid-related form: curable with complete tumor resection. Management of hypercortisolism is directly linked to survival. |
| 12. Prevention | Smoking cessation (reduces lung cancer risk). Regular screening in families with hereditary neuroendocrine tumors. Primary prevention of ectopic ACTH syndrome itself is not possible. Early tumor detection increases the chance of cure. |
| 13. References | Meador CK, Liddle GW, Island DP, et al. Cause of Cushing's syndrome in patients with tumors arising from "nonendocrine" tissue. 1962 … and 9 other papers |
The history of ectopic ACTH syndrome began in the early 20th century when clinicians observed clinical features of hypercortisolism in patients with malignant tumors of the lung or abdominal cavity. In 1928, the British physician W. H. Brown first reported bilateral adrenal hypertrophy and symptoms of hypercortisolism in a patient with oat cell carcinoma of the lung (oat cell carcinoma, today's small cell lung cancer). At the time, however, this phenomenon was not understood to be due to a direct hormonal link between the lung tumor and adrenal function, and it tended to be interpreted as incidental hyperplasia of the adrenal glands themselves.
1962 was a decisive year for establishing the concept of ectopic ACTH syndrome. The American endocrinologists Clive K. Meador, Grant W. Liddle, David P. Island and colleagues published a landmark paper in the Journal of Clinical Endocrinology and Metabolism, "Cause of Cushing's syndrome in patients with tumors arising from nonendocrine tissue". In this paper, the authors demonstrated biochemically that various tumors arising from tissues other than the pituitary (then called "nonendocrine tissue") can autonomously secrete ACTH or ACTH-like substances and cause Cushing syndrome. In particular, they confirmed this phenomenon in oat cell carcinoma of the lung and thymoma. Through this paper the concept of 'ectopic' ACTH secretion was established.
Subsequently, in 1969, Liddle et al. described that ectopic ACTH syndrome often presents only with severe muscle weakness and hypokalemic alkalosis without the typical cushingoid appearance (obesity, striae, etc.), pointing out that this rapid clinical course reflects the high malignancy of the primary tumor. In the 1970s–80s, as technologies such as ACTH measurement by radioimmunoassay (RIA), CT imaging and indium-111–labeled somatostatin receptor scintigraphy developed, localization of tumors secreting ectopic ACTH was systematized.
From the 1990s, inferior petrosal sinus sampling (IPSS) became established as the reference test for distinguishing ectopic ACTH syndrome from Cushing disease, and 68Ga-DOTATATE PET-CT made an innovative contribution to identifying neuroendocrine tumors expressing somatostatin receptors, greatly improving the diagnostic rate of occult ectopic ACTH tumors. Since the 2000s, research has become active on the molecular mechanisms involved in regulating POMC gene expression, that is, on how epigenetic changes in tumor cells permit POMC transcription that should be suppressed in normal tissue.
The defining feature of ectopic ACTH syndrome is that tumor cells of tissues other than the pituitary autonomously secrete ACTH or its precursor pro-opiomelanocortin (POMC). Normally the POMC gene is expressed mainly in the corticotroph cells of the anterior pituitary, and in other tissues its expression is strictly blocked by suppressive mechanisms. When this suppression is released in tumor cells and ACTH is secreted in large amounts, ectopic ACTH syndrome develops.
Among causative tumors, small cell lung carcinoma (SCLC) is the most common at about 50%. SCLC is a highly malignant tumor showing neuroendocrine differentiation and tends to express various hormone precursors. Next, bronchial carcinoid accounts for 10–15%; unlike SCLC it is a low-grade malignant tumor, so the course of ectopic ACTH syndrome is more chronic and a cushingoid appearance may be clearly evident. In addition, thymic carcinoid, pancreatic neuroendocrine tumor (pancreatic NET), pheochromocytoma/gangliocytoma, gastrointestinal carcinoid, medullary thyroid carcinoma, breast cancer, prostate cancer and colorectal cancer can also rarely secrete ectopic ACTH.
The clinical picture of ectopic ACTH syndrome is closely related to the malignancy of the primary tumor. In the SCLC-related form, ACTH levels are extremely high and cortisol excess progresses very rapidly, so hypokalemia, proximal muscle weakness and hyperpigmentation are more prominent than the typical cushingoid appearance. In contrast, in benign or low-grade malignant carcinoid tumors, ACTH secretion increases relatively gradually, and a cushingoid appearance develops progressively over months to years. This latter form is clinically similar to pituitary-dependent Cushing disease, causing considerable difficulty in differential diagnosis.
In about 10% of cases, it presents as occult ectopic ACTH syndrome, in which the primary tumor is not found on any imaging study. In these cases a small carcinoid (especially bronchial or thymic carcinoid) or a microscopic neuroendocrine tumor is often the cause, and sophisticated imaging and functional nuclear medicine studies must be repeated to localize the tumor.
The genetics of primary tumors causing ectopic ACTH syndrome differ by tumor type. Small cell lung cancer (SCLC), the most common cause, is a highly heterogeneous tumor in which simultaneous inactivation of TP53 (17p13) and RB1 (13q14) is almost universally observed. In addition, MYCL and MYCN amplification and CREBBP and EP300 variants are frequently found in SCLC. Proposed molecular mechanisms permitting ectopic POMC expression in SCLC include epigenetic release of POMC gene suppression through CpG island hypomethylation and overexpression of neuroendocrine transcription factors (ASCL1, NEUROD1).
In bronchial carcinoids, somatic or germline variants of MEN1 (11q13) are most frequently reported, and some occur as part of multiple endocrine neoplasia type 1 (MEN1). In carriers of MEN1 germline variants, the risk of bronchial carcinoid increases, and associated ectopic ACTH syndrome is not uncommon. In pancreatic neuroendocrine tumors, besides MEN1, DAXX/ATRX variants and variants in mTOR pathway genes (TSC2, PTEN) are characteristic.
Ectopic ACTH syndrome associated with pheochromocytoma and paraganglioma is highly heritable and may be related to germline variants of RET (MEN2 syndrome), VHL, NF1, SDHB/SDHD/SDHC and others. Medullary thyroid carcinoma occurs sporadically or as part of MEN2A/MEN2B (RET germline variants), and cases of ectopic ACTH secretion have been reported. Thus, when ectopic ACTH syndrome is diagnosed, it is important to assess the need for genetic testing according to the type of primary tumor.
From a clinical genetics standpoint, in highly malignant primary tumors such as SCLC, acquired (somatic) variants predominate and the need for genetic counseling is low, but for carcinoids, pheochromocytomas and medullary carcinomas, germline genetic testing (MEN1, RET, VHL, SDH gene panel) is recommended to rule out hereditary causes. Identifying MEN1 or MEN2 makes it possible to offer preventive screening to family members and provide an opportunity for early detection.
Ectopic ACTH syndrome is the third most common cause of endogenous Cushing syndrome, accounting for about 10–20% of the total. The distribution is Cushing disease (pituitary-dependent) 70–80%, primary adrenal adenoma/carcinoma 10%, and ectopic ACTH syndrome the remainder. The absolute incidence is estimated at about 0.5–2 per million population per year, but because this indirectly reflects the incidence of the primary tumors, accurate estimation is difficult.
The sex distribution varies with the characteristics of the primary tumor. SCLC-related ectopic ACTH syndrome was previously male predominant, but with changes in lung cancer epidemiology (increased smoking among women), the sex difference is now decreasing. The bronchial carcinoid–related form tends to be more common in women. By age, the SCLC-related form is most common in the 50s–70s, while the carcinoid-related form shows a relatively wide age distribution from the 30s to the 60s.
Ectopic ACTH syndrome accompanies about 1–5% of small cell lung cancers (SCLC). Since SCLC accounts for about 15% of all lung cancers, ectopic ACTH secretion in SCLC explains more than half of ectopic ACTH syndrome cases. Bronchial carcinoid is the second most common cause of ectopic ACTH syndrome, accounting for about 10–15%. Thymic carcinoid and pancreatic neuroendocrine tumors follow at 5–10% each, and pheochromocytoma/paraganglioma at about 5%.
In Korea, lung cancer is frequent and SCLC accounts for about 15–20% of it, so a substantial portion of ectopic ACTH syndrome is expected to be associated with SCLC. Analysis of the domestic characteristics of ectopic ACTH syndrome in Korean multicenter studies is limited, but overall the distribution of causative tumors is similar to Western reports. In occult ectopic ACTH syndrome caused by bronchial or thymic carcinoid, delayed diagnosis has also been reported in Korea.
The core pathogenetic mechanism of ectopic ACTH syndrome is ectopic expression of the POMC gene in non-pituitary tumor cells. In normal adults, POMC is expressed mainly in the corticotroph cells of the anterior pituitary, the intermediate lobe and some nuclei of the brain, and is strictly suppressed in other tissues. This suppression is maintained mainly by CpG island methylation of the POMC promoter region and repressive transcription factors. When this epigenetic suppression mechanism is released during tumorigenesis, such as by demethylation, POMC transcription is activated in tumor cells of non-corticotroph lineage, and ACTH precursors are synthesized in large amounts.
The synthesized POMC is processed by prohormone convertases in the tumor cells (mainly PC2, in some cases PC1/PC3) into ACTH, β-LPH, β-endorphin and, in some cases, α-MSH and β-MSH. Unlike in the normal pituitary, POMC processing in tumor cells is often incomplete or abnormal, so unprocessed high-molecular-weight ACTH precursors (big-ACTH, pro-ACTH) may be released into the blood. These abnormal precursors can also stimulate cortisol synthesis via the ACTH receptor (MC2R) of the adrenal cortex.
Ectopically secreted ACTH enters the blood and strongly stimulates both adrenal cortices, causing cortisol to be produced at extremely high levels. This excess cortisol should normally exert negative feedback on pituitary corticotroph cells, but the primary tumor does not respond to this feedback signal, so ACTH secretion continues unsuppressed. Moreover, as cortisol levels rise, the 11β-HSD2 (11β-hydroxysteroid dehydrogenase 2) enzyme becomes saturated and mineralocorticoid effects appear, causing severe hypokalemic alkalosis. This is why hypokalemia is characteristically prominent in ectopic ACTH syndrome.
In aggressive tumors such as SCLC, ACTH secretion is very rapid and cortisol levels rise quickly, so acute metabolic abnormalities (hypokalemia, hyperglycemia, hypertension) appear first, without the months needed for typical central obesity and striae to form. In contrast, the slow growth and gradual ACTH secretion of carcinoid tumors allow chronic hypercortisolism, producing a distinct cushingoid appearance, which is why it is clinically confused with Cushing disease.
The clinical symptoms of ectopic ACTH syndrome can appear in two extreme forms depending on the malignancy of the primary tumor. The first is the acute, severe form associated with SCLC or other highly malignant tumors. In this form, cortisol rises so rapidly that there is no time for the typical cushingoid appearance (central obesity, moon face, buffalo hump) to develop. Instead, the main symptoms are severe proximal muscle weakness (inability to climb stairs, difficulty raising the arms), palpitations, limb paralysis and respiratory muscle weakness due to hypokalemia, severe hypertension, abrupt-onset diabetes or worsening glycemic control, generalized edema and hyperpigmentation of the skin and mucous membranes.
The second is the chronic, gradual form associated with low-grade malignant tumors such as bronchial carcinoid. In this case, typical Cushing symptoms that are difficult to distinguish from Cushing disease—weight gain, facial obesity, hypertension, diabetes, osteoporosis, depression, skin striae—develop over months to years. Patients with this form are often misdiagnosed with Cushing disease, and even after undergoing surgery no tumor is found, further delaying diagnosis.
Systemically, severe fatigue and weakness are common, and the risk of opportunistic infections (oral candidiasis, Pneumocystis pneumonia) is high. Immunosuppression may accelerate progression of the existing tumor. The risk of thromboembolism (DVT, pulmonary embolism) is markedly increased. Symptoms due to the primary tumor (cough, dyspnea, chest pain, abdominal pain, skin lesions) may be present, and these sometimes provide a clue to the diagnosis of ectopic ACTH syndrome.
The characteristic laboratory finding of ectopic ACTH syndrome is severe hypokalemia, with serum potassium often below 3.0 mEq/L and in severe cases falling below 2.0 mEq/L. This is because extremely high cortisol saturates the renal mineralocorticoid receptors and promotes renal potassium excretion. The pattern of hypokalemic alkalosis is an important clue for distinguishing ectopic ACTH syndrome from Cushing disease.
Plasma ACTH usually shows extremely high values well above 200 pg/mL, reaching thousands to tens of thousands of pg/mL in some SCLC patients. Serum cortisol often shows extremely high values of 50 μg/dL or more. 24-hour urinary free cortisol (UFC) is commonly more than 10 times the upper limit of normal. Cortisol is not suppressed on the 8 mg dexamethasone suppression test (no response), an important point of differentiation from Cushing disease (generally suppressed by 50% or more).
Skin hyperpigmentation results from the melanocyte-stimulating effect of MSH and ACTH and is particularly marked in the oral mucosa, palmar creases and scars. On physical examination, proximal muscle weakness is prominent, and reduced reflexes and distal limb sensory abnormalities may be present. Hypertension, hyperglycemia and edema are found in most patients. On IPSS, a central:peripheral ACTH ratio below 2.0 (basal) or below 3.0 (after CRH stimulation) supports ectopic secretion.
Screening for ectopic ACTH syndrome generally begins in two clinical situations. The first is to exclude hypercortisolism in patients with prominent metabolic abnormalities without a typical cushingoid appearance, such as unexplained hypokalemia, abrupt onset or worsening of diabetes, severe hypertension and proximal muscle weakness. The second is to evaluate for ectopic hormone secretion in patients in whom a neuroendocrine tumor (SCLC, carcinoid, pancreatic NET, etc.) has already been identified.
As screening tests, 24-hour urinary free cortisol (UFC), two measurements of late-night salivary cortisol and the 1 mg overnight dexamethasone suppression test are performed as standard. In ectopic ACTH syndrome, UFC and serum cortisol are very high, so screening tests often give clearly positive results. Along with these, plasma ACTH, serum potassium, blood glucose and blood gas analysis (to confirm hypokalemic alkalosis) are measured simultaneously at the outset.
If ectopic ACTH syndrome is suspected, a high-dose dexamethasone suppression test is performed immediately to begin differentiation from Cushing disease. When there is severe hypokalemia, ECG monitoring and potassium supplementation must be carried out urgently in parallel with screening. When ACTH is 200 pg/mL or more and cortisol is 50 μg/dL or more, the likelihood of ectopic ACTH syndrome is very high.
Confirmation of ectopic ACTH syndrome is a stepwise process: ① confirmation of hypercortisolism, ② confirmation of ACTH dependence, ③ confirmation of ectopic secretion (IPSS), and ④ localization of the primary tumor.
Confirmation of ACTH dependence: ACTH dependence is confirmed by plasma ACTH >10 pg/mL. High-dose dexamethasone suppression test: if serum cortisol is not suppressed by 50% or more of baseline after 8 mg of dexamethasone, ectopic ACTH syndrome is strongly suggested (it is mostly suppressed in Cushing disease). However, there are exceptions, so IPSS is essential. IPSS: simultaneous ACTH measurement in the inferior petrosal sinuses and a peripheral vein, at baseline and after intravenous CRH 100 μg. A central:peripheral ratio <2.0 (basal) or <3.0 (after CRH) supports ectopic secretion.
Localization of the primary tumor: ① Chest, abdominal and pelvic CT (thin-section, high-resolution) is the first-line imaging. ② Somatostatin receptor scintigraphy (68Ga-DOTATATE PET-CT) is highly sensitive for detecting carcinoids and pancreatic NETs that express somatostatin receptors and is the standard functional imaging for searching for occult ectopic ACTH tumors. ③ FDG-PET CT is useful for highly malignant tumors with active glucose metabolism, such as SCLC. ④ MRI complements CT for detailed evaluation of chest and abdominal tumors. If all imaging is negative, imaging follow-up at 6–12-month intervals and 68Ga-DOTATATE PET-CT are repeated.
Histologic diagnosis is confirmed by ACTH immunohistochemical staining of resected tumor specimens or biopsy tissue. For carcinoids in particular, the neuroendocrine nature is verified by confirming expression of synaptophysin and chromogranin A.
Treatment of ectopic ACTH syndrome consists of two axes: ① treatment of the primary tumor and ② immediate control of hypercortisolism.
Treatment of the primary tumor is the most effective way to resolve hypercortisolism. When surgical resection is possible (bronchial carcinoid, thymic carcinoid, some pancreatic NETs), complete resection can cure ectopic ACTH syndrome. Confirmation of normalization of cortisol and ACTH after surgery is taken as the criterion for cure. For SCLC, chemotherapy (etoposide-cisplatin–based) and radiotherapy are first-line treatment, and ACTH levels may decrease when the tumor responds.
Urgent control of hypercortisolism is needed at the same time. Immediate correction of hypokalemia (intravenous potassium supplementation) is the top priority. The following cortisol synthesis inhibitors are used: ketoconazole (oral, 600–1,200 mg/day, requires monitoring for hepatotoxicity), metyrapone (oral, 2–4g/day, rapid onset of effect), etomidate (intravenous, 0.3 mg/kg/hr, used for decreased consciousness or preoperative emergencies), mitotane (oral, adrenocytotoxic, slow-acting). Recently osilodrostat, pasireotide and others are also used.
When hypercortisolism cannot be controlled, or is insufficiently controlled, by surgical or pharmacologic means, bilateral adrenalectomy may be performed as a definitive method. In this case, lifelong hydrocortisone and fludrocortisone replacement is required. Somatostatin receptor agonists (octreotide LAR, pasireotide) may be expected to suppress ACTH secretion and tumor growth in carcinoids.
The prognosis of ectopic ACTH syndrome is largely determined by the malignancy of the primary tumor. The prognosis is worst in the SCLC-associated form. The median survival of SCLC itself is 7–12 months in extensive stage, and when ectopic ACTH syndrome is present, survival is further shortened by immunosuppression, susceptibility to infection and thromboembolism due to hypercortisolism. In one study, the median survival of SCLC patients with ectopic ACTH syndrome was about 4.5 months when hypercortisolism was controlled and only 1–2 months when it was not. Thus, control of cortisol levels is an independent predictor of survival in SCLC.
In contrast, ectopic ACTH syndrome due to bronchial carcinoid or other low-grade malignant neuroendocrine tumors can be cured with complete tumor resection, and long-term survival is expected. In these patients, many cases have been reported with normalization of cortisol and ACTH and complete resolution of symptoms after surgery and recurrence-free survival of more than 10 years. However, the prognosis of carcinoids also worsens when there is local invasion or distant metastasis.
In occult ectopic ACTH syndrome, a strategy is used in which hypercortisolism is first controlled by bilateral adrenalectomy until the primary tumor is localized, followed by an ongoing search for the tumor. The long-term prognosis of these patients ultimately depends on the timing of tumor detection and resectability. Overall, early detection of ectopic ACTH syndrome, rapid control of hypercortisolism and complete removal of the primary tumor are key to improving prognosis.
There is no method of primary prevention of ectopic ACTH syndrome itself. This is because the occurrence of the primary tumor would need to be prevented; in the case of SCLC, smoking cessation greatly lowers the overall risk of lung cancer and can indirectly reduce the occurrence of ectopic ACTH syndrome. Public health policies to reduce smoking rates in Korea may reduce the burden of SCLC-related ectopic ACTH syndrome in the long term. For most other causative tumors (carcinoid, pancreatic NET, etc.) there is no clear primary prevention method.
To prevent forms related to hereditary neuroendocrine tumors, it is important to detect primary tumors early by performing regular screening of families carrying MEN1, MEN2, VHL and SDH gene variants. In patients with MEN1 syndrome, chest CT is performed every 2–3 years to monitor for bronchial carcinoid, and if a carcinoid is found, it is evaluated for ectopic ACTH secretion as well.
For secondary prevention (prevention of complications) of ectopic ACTH syndrome, preventing complications related to hypercortisolism (hypokalemia, infection, thrombosis, worsening diabetes) is important. Detecting ectopic ACTH syndrome early, including endocrine function assessment at the time of primary tumor diagnosis, and starting cortisol synthesis inhibitor treatment immediately can minimize treatment-related complications and improve tolerance of primary tumor treatment (chemotherapy, etc.). In carcinoid-related ectopic ACTH syndrome, cure is possible with early surgical resection, so rapid tumor localization and surgical referral are the key to secondary prevention.